List view / Grid view

Dr Christopher Haqq (Elicio)

 

article

The future of cancer immunotherapy with Elicio Therapeutics

In this exclusive interview with Dr Christopher Haqq, Executive Vice…

1 March 2024 | By ,

In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…